Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4317 Late diagnosis of MEN2A syndrome: Ten cases in one family

Introduction: Multiple endocrine neoplasia type 2 (MEN2) constitutes a rare hereditary cancer syndrome affecting various endocrine glands.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Dzeranova L, Przhiyalkovskaya E, Pigarova E,

Keywords: MEN2A, RET, MTC, THYROIDECTOMY,

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,

#3781 Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,

#3779 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,

#3683 Distinct clinico-pathological features of neuroendocrine liver metastases originating from the pancreas and rectum

Introduction: The treatment response and prognosis still remain poor in the metastatic neuroendocrine neoplasms.

Conference:

Presenting Author: Takahiro T

Authors: Tsuchikawa T, Aya M, Tanaka K, Nakanishi Y, Asano T,

Keywords: Neuroendocrine liver metastasis, pancreas, rectum, clinical characteristics,